Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

MLA

Fraser, G., et al. Updated Results from the Phase 3 HELIOS Study of Ibrutinib, Bendamustine, and Rituximab in Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1201315966&authtype=sso&custid=ns315887.

APA

Fraser, G., Cramer, P., Demirkan, F., Silva, R. S., Grosicki, S., Pristupa, A., Janssens, A., Mayer, J., Bartlett, N. L., Dilhuydy, M.-S., Pylypenko, H., Loscertales, J., Avigdor, A., Rule, S., Villa, D., Samoilova, O., Panagiotidis, P., Goy, A., Pavlovsky, M. A., … Chanan-Khan, A. (2019). Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.

Chicago

Fraser, G., P. Cramer, F. Demirkan, R. Santucci Silva, S. Grosicki, A. Pristupa, A. Janssens, et al. 2019. “Updated Results from the Phase 3 HELIOS Study of Ibrutinib, Bendamustine, and Rituximab in Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1201315966&authtype=sso&custid=ns315887.